CTSOHealthcare · Medical DevicesThe 1 Wall Street analysts covering CytoSorbents Corp. hold a median 12-month price target of $48 — +806.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores CytoSorbents Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (22): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CTSO, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +806.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | WBB Securities | Initiates | Speculative Buy | $9.50 |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | $10 |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 12 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 16 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 May 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 2 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 1 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CTSO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 84% of US stocks
Cheaper than 98% of US stocks
Cheaper than 79% of US stocks
Higher than 28% of US stocks
Higher than 36% of US stocks
Higher than 85% of US stocks
Higher than 20% of US stocks
Higher than 10% of US stocks
Higher than 5% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CytoSorbents Corp. has a market value of $15.3M and an enterprise value of $40.3M.
Revenue in the twelve months to 30 June 2026: $37.2M. The latest quarter grew 0.2% year on year.
Net income over the same four quarters: −$18.2M, a −48.9% net margin.
Diluted earnings per share, trailing twelve months: $−5.80.
Free cash flow in the twelve months to 30 June 2026: −$9.6M.
Trailing P/E: −1.8×; forward P/E: −5.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CytoSorbents Corp. employs 129 people — $288K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CytoSorbents Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CytoSorbents announced it will report third-quarter 2026 financial results and recent business highlights after market close on Thursday, November 12, 2026.
Why it matters — CTSO watchers may note the scheduled date for the company’s financial results and business update.
CytoSorbents announced that it will present new data on its CytoSorb blood purification technology at the European Association for Cardio-Thoracic Surgery Annual Meeting in Barcelona (October 7-10, 2026) and at the European Society of Intensive Care Medicine Annual Congress in Lisbon (October 10-14, 2026), covering open heart surgery and critical care applications.
Why it matters — The upcoming presentations highlight CytoSorb's clinical evidence across cardiac surgery and critical care at major international conferences, which could raise the product's visibility among key medical professionals.
CytoSorbents Corporation announced that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share. The company, which uses blood purification to treat life-threatening conditions in the ICU and cardiac surgery, made the announcement on September 23, 2026.
Why it matters — Regaining compliance removes the risk of delisting from Nasdaq, which is material to CTSO shareholders and the company's continued listing status.
CytoSorbents Corporation announced it will participate in the upcoming H.C. Wainwright 28th Annual Global Investment Conference, as disclosed in a Sept. 10, 2026 press release from Princeton, N.J. The company, which specializes in blood purification for life-threatening conditions in the intensive care unit and cardiac surgery, noted its attendance at the event.
Why it matters — A CTSO watcher would care because the company's participation at a major investment conference provides an opportunity for leadership to present to investors and potentially raise its visibility in the financial community.
CytoSorbents announced that CEO Dr. Phillip Chan and CFO Peter Mariani will attend the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9-10, 2026, in New York City, where they will deliver an investor presentation and hold scheduled one-on-one meetings with investors.
Why it matters — CTSO watchers may be interested because the company executives are engaging directly with investors at a life sciences conference, providing an opportunity to share updates on the company.
The 1 Wall Street analysts covering CytoSorbents Corp. have a median 12-month price target of $48, with estimates ranging from $15 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering CytoSorbents Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytoSorbents Corp. 50 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, CytoSorbents Corp. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +806.5% from the last close, and Ticker Nerd's factor model ranks CytoSorbents Corp. 50 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CytoSorbents Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTSO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $80 over the next 12 months.
CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs.
The most recent item we track (PRNewsWire, 29 Oct 2026): "CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights". CytoSorbents announced it will report third-quarter 2026 financial results and recent business highlights after market close on Thursday, November 12, 2026.
CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs. Its portfolio includes CytoSorb for intensive care and surgical applications, DrugSorb-ATR for removing blood thinners, and additional blood purification and filtration technologies for specialized clinical and veterinary uses. The company serves hospitals and clinicians in the United States, Europe, and other international markets, with an emphasis on treating life-threatening conditions such as sepsis, severe inflammation, and complications associated with surgery and organ failure. Headquartered in Princeton, New Jersey, CytoSorbents Corporation plays a niche role in the medical technology market through its proprietary polymer-based adsorption platform.
CEO Dr. Phillip P. Chan M.D., Ph.D. · 129 employees · United States · https://www.cytosorbents.com